Richmond Behavioral Associates

Running trials

• Not yet recruiting

  A Study of Brenipatide in Participants With Major Depressive Disorder

  NCT07928245· Phase 2· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

  NCT07140913· Phase 3· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)

  NCT07172516· Phase 3· Source

• Recruiting

  A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

  NCT06929273· Phase 3· Source

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

  NCT07011745· Phase 3· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

  NCT06951698· Phase 3· Source

• Active, not recruiting

  An Open-Label Study of Azetukalner in Major Depressive Disorder

  NCT06922110· Phase 3· Source

• Active, not recruiting

  A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD

  NCT06709014· Phase 3· Source

• Active, not recruiting

  A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder

  NCT06775379· Phase 3· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

  NCT06706674· Phase 3· Source

• Recruiting

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· Phase 3· Source

• Active, not recruiting

  ML-004 Open-Label Extension Study in Adults and Adolescents With Autism Spectrum Disorders (ASD)

  NCT05889273· Phase 2· Source

• Active, not recruiting

  Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With TRD

  NCT05711940· Phase 3· Source

• Active, not recruiting

  A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

  NCT05026866· Phase 3· Source

• Active, not recruiting

  A Study of Donanemab (LY3002813) in Participants With Early Alzheimer's Disease (TRAILBLAZER-ALZ 2)

  NCT04437511· Phase 3· Source

• Active, not recruiting

  ERG Components in Schizophrenia and Bipolar Disorder Type I

  NCT03788811· Source

• Active, not recruiting

  An Open Label Study of CM-AT for the Treatment of Children With Autism

  NCT02649959· Phase 3· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Bipolar disorder4 recruiting
• Autism2 recruiting
• Alzheimer disease1 recruiting
• Depression1 recruiting
• Schizophrenia1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

  NCT07046494· Phase 2· Source

• Completed

  Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients

  NCT06836063· Phase 2· Source

• Completed

  A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia

  NCT06791122· Source

• Completed

  Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia

  NCT06179108· Phase 2· Source

• Terminated

  Open-label Extension for Phase 3 Clinical Trials of Simufilam

  NCT05575076· Phase 3· Source

• Completed

  ML-004 in Adolescents and Adults With Autism Spectrum Disorders (ASD)

  NCT05081245· Phase 2· Source

• Completed

  Trial of Centanafadine Efficacy and Safety as Monotherapy or as Adjunct to SSRI in Adults With Major Depressive Disorder

  NCT05536414· Phase 2· Source

• Completed

  A Study of Seltorexant in Participants With Probable Alzheimer's Disease

  NCT05307692· Phase 2· Source

• Terminated

  Simufilam 50 mg or 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT05026177· Phase 3· Source

• Completed

  Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder

  NCT04745026· Phase 2· Source

• Completed

  An Efficacy and Safety Study of ALZ-801 in APOE4/4 Early AD Subjects

  NCT04770220· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE)

  NCT04777396· Phase 3· Source

• Completed

  A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)

  NCT04777409· Phase 3· Source

• Recruiting

  A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression

  NCT03887715· Source

• Terminated

  Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

  NCT02446132· Phase 3· Source